GlassScriptPhysician profile
Norman Brodsky
NPI 1427025196
$267.36
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $19.40 · 2022: $13.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.73 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.37 | 2019 | |
| Daiichi Sankyo INC. | $24.74 | 2019 | |
| Seagen INC. | $24.08 | 2019 | |
| Amgen INC. | $17.80 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.06 | 2019 | |
| Astellas Pharma US INC | $14.55 | 2019 | |
| Janssen Biotech, INC. | $13.63 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.24 | 2019 | |
| Rigel Pharmaceuticals, INC. | $11.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Brodsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.